OA12340A - Mélanges de polysaccharides dérivés d'héparine, leur préparation et les compositions pharmaceutiquesles contenant. - Google Patents

Mélanges de polysaccharides dérivés d'héparine, leur préparation et les compositions pharmaceutiquesles contenant. Download PDF

Info

Publication number: OA12340A
Authority: OA; OAPI
Prior art keywords: heparin; activity; benzyl ester; sodium; salt
Prior art date: 2000-07-21

Application number

OA1200300012A

Other languages

English (en)

French (fr)

Inventor

Jacques Diaz

Christelle Pecquet

Elisabeth Perrin

Christian Viskov

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-21

Filing date

2001-07-18

Publication date

2006-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8852768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12340(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-18 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2006-05-15 Publication of OA12340A publication Critical patent/OA12340A/fr

Links

229920000669 heparin Polymers 0.000 title claims abstract description 57
239000000203 mixture Substances 0.000 title claims abstract description 53
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 41
229960002897 heparin Drugs 0.000 title claims abstract description 40
150000004676 glycans Chemical class 0.000 title claims abstract description 16
229920001282 polysaccharide Polymers 0.000 title claims abstract description 16
239000005017 polysaccharide Substances 0.000 title claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
238000002360 preparation method Methods 0.000 title claims abstract description 6
-1 benzyl ester Chemical class 0.000 claims description 58
159000000000 sodium salts Chemical class 0.000 claims description 58
230000000694 effects Effects 0.000 claims description 48
239000003055 low molecular weight heparin Substances 0.000 claims description 28
238000000034 method Methods 0.000 claims description 25
230000001858 anti-Xa Effects 0.000 claims description 23
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 20
239000001632 sodium acetate Substances 0.000 claims description 20
235000017281 sodium acetate Nutrition 0.000 claims description 20
238000007127 saponification reaction Methods 0.000 claims description 16
230000032050 esterification Effects 0.000 claims description 15
238000005886 esterification reaction Methods 0.000 claims description 15
238000000746 purification Methods 0.000 claims description 14
150000003242 quaternary ammonium salts Chemical class 0.000 claims description 14
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical class C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 claims description 9
230000009466 transformation Effects 0.000 claims description 8
239000002585 base Substances 0.000 claims description 6
150000007530 organic bases Chemical class 0.000 claims description 6
229910052708 sodium Inorganic materials 0.000 claims description 6
239000011734 sodium Substances 0.000 claims description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
FVKFHMNJTHKMRX-UHFFFAOYSA-N 3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidine Chemical compound C1CCN2CCCNC2=N1 FVKFHMNJTHKMRX-UHFFFAOYSA-N 0.000 claims description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
150000008044 alkali metal hydroxides Chemical class 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
239000012429 reaction media Substances 0.000 claims description 4
VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
230000001476 alcoholic effect Effects 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
ITAWMPSVROAMOE-UHFFFAOYSA-N sodium;imidazol-3-ide Chemical compound [Na+].C1=C[N-]C=N1 ITAWMPSVROAMOE-UHFFFAOYSA-N 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 claims description 2
229960004830 cetylpyridinium Drugs 0.000 claims description 2
239000000470 constituent Substances 0.000 claims description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
230000003110 anti-inflammatory effect Effects 0.000 claims 1
229940127217 antithrombotic drug Drugs 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000011777 magnesium Substances 0.000 claims 1
229910052749 magnesium Inorganic materials 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 148
239000002244 precipitate Substances 0.000 description 63
239000000243 solution Substances 0.000 description 34
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
239000000725 suspension Substances 0.000 description 26
238000003756 stirring Methods 0.000 description 23
239000006228 supernatant Substances 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000007787 solid Substances 0.000 description 15
238000001035 drying Methods 0.000 description 13
238000003760 magnetic stirring Methods 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
229960003872 benzethonium Drugs 0.000 description 12
239000013049 sediment Substances 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000011521 glass Substances 0.000 description 10
239000000843 powder Substances 0.000 description 9
239000002002 slurry Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000004090 dissolution Methods 0.000 description 7
239000012153 distilled water Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
229910052784 alkaline earth metal Inorganic materials 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
239000012736 aqueous medium Substances 0.000 description 4
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 4
229940073608 benzyl chloride Drugs 0.000 description 4
239000003205 fragrance Substances 0.000 description 4
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229940127215 low-molecular weight heparin Drugs 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
229960001950 benzethonium chloride Drugs 0.000 description 2
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 2
IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
COEZWFYORILMOM-UHFFFAOYSA-M sodium 4-[(2,4-dihydroxyphenyl)diazenyl]benzenesulfonate Chemical compound [Na+].OC1=CC(O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 COEZWFYORILMOM-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
238000001159 Fisher's combined probability test Methods 0.000 description 1
102100021194 Glypican-6 Human genes 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000001147 anti-toxic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical class [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
238000001816 cooling Methods 0.000 description 1
YYBBWTWVCKKUGB-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1[CH+]C=CC=C1 YYBBWTWVCKKUGB-UHFFFAOYSA-N 0.000 description 1
UURSXESKOOOTOV-UHFFFAOYSA-N dec-5-ene Chemical compound CCCCC=CCCCC UURSXESKOOOTOV-UHFFFAOYSA-N 0.000 description 1
238000012691 depolymerization reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
ZAASRHQPRFFWCS-UHFFFAOYSA-P diazanium;oxygen(2-);uranium Chemical compound [NH4+].[NH4+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[U].[U] ZAASRHQPRFFWCS-UHFFFAOYSA-P 0.000 description 1
MUJOVVKDDICVMS-UHFFFAOYSA-N diazaphosphinine Chemical compound C1=CN=NP=C1 MUJOVVKDDICVMS-UHFFFAOYSA-N 0.000 description 1
239000003480 eluent Substances 0.000 description 1
229960000610 enoxaparin Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229940045627 porcine heparin Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940061706 sulfated mucopolysaccharides Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Polymers & Plastics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

OA1200300012A 2000-07-21 2001-07-18 Mélanges de polysaccharides dérivés d'héparine, leur préparation et les compositions pharmaceutiquesles contenant. OA12340A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0009572A FR2811992B1 (fr)	2000-07-21	2000-07-21	Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number	Publication Date
OA12340A true OA12340A (fr)	2006-05-15

Family

ID=8852768

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300012A OA12340A (fr)	2000-07-21	2001-07-18	Mélanges de polysaccharides dérivés d'héparine, leur préparation et les compositions pharmaceutiquesles contenant.

Country Status (35)

Country	Link
EP (1)	EP1307491B2 (de)
JP (1)	JP5279160B2 (de)
KR (1)	KR100853585B1 (de)
CN (1)	CN1230449C (de)
AP (1)	AP1703A (de)
AR (1)	AR029865A1 (de)
AT (1)	ATE470679T1 (de)
AU (2)	AU2001277602B2 (de)
BR (1)	BR0112612B1 (de)
CA (1)	CA2416673C (de)
CL (1)	CL2004001154A1 (de)
CY (1)	CY1110774T1 (de)
DE (1)	DE60142340D1 (de)
DK (1)	DK1307491T3 (de)
DZ (1)	DZ3411A1 (de)
EA (1)	EA005995B1 (de)
EC (1)	ECSP034442A (de)
ES (1)	ES2347134T5 (de)
FR (1)	FR2811992B1 (de)
HR (1)	HRP20030019A2 (de)
HU (1)	HUP0300755A3 (de)
IL (2)	IL153922A0 (de)
MA (1)	MA26928A1 (de)
MX (1)	MXPA03000579A (de)
NO (1)	NO20030296L (de)
NZ (1)	NZ524028A (de)
OA (1)	OA12340A (de)
PL (1)	PL202471B1 (de)
PT (1)	PT1307491E (de)
SI (1)	SI1307491T1 (de)
TW (1)	TWI307278B (de)
UA (1)	UA74836C2 (de)
WO (1)	WO2002008295A1 (de)
YU (1)	YU2903A (de)
ZA (1)	ZA200300898B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6969705B2 (en)	2000-07-21	2005-11-29	Aventis Pharma S.A.	Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
DE60218642T2 (de) *	2002-06-20	2007-11-29	Chemi S.P.A., Cinisello Balsamo	Verfahren zur Herstellung von Heparinestern
US20040171819A1 (en)	2002-10-10	2004-09-02	Aventis Pharma S.A.	Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
AR041555A1 (es)	2002-10-10	2005-05-18	Aventis Pharma Sa	Mezclas de polisacaridos derivados de heparina, su preparacion y las composiciones farmaceuticas que las contienen
FR2845686B1 (fr) *	2002-10-10	2013-08-30	Aventis Pharma Sa	Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US7956046B2 (en) *	2003-07-24	2011-06-07	Aventis Pharma S.A.	Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
FR2857971B1 (fr) *	2003-07-24	2005-08-26	Aventis Pharma Sa	Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
DE102004059134B4 (de)	2004-12-08	2011-12-15	Siemens Ag	Expansionsvorrichtung für ein Röntgengerät und Röntgenstrahler
FR2889078B1 (fr) *	2005-07-27	2007-11-02	Aventis Pharma Sa	Nouvelle methode de chromatographie d'affinite d'antithrombine iii
CA2652205A1 (en) *	2006-05-25	2007-12-06	Mallik Sundaram	Low molecular weight heparin composition and uses thereof
CN101824099B (zh) *	2010-02-12	2011-11-30	淮安麦德森化学有限公司	一种粗品肝素钠的纯化方法
CN101824446B (zh) *	2010-02-24	2012-12-12	淮安麦德森化学有限公司	反向沉淀生产硫酸软骨素的方法
EP2399592A1 (de)	2010-06-25	2011-12-28	Aventis Pharma S.A.	Semuloparin zur Prävention eines Mortalitäts- und/oder Morbiditätsereignisses bei einem Patienten, an dem ein schwerer chirurgischer Eingriff vorgenommen wird
EP2399591A1 (de)	2010-06-25	2011-12-28	Aventis Pharma S.A.	Semuloparin zur Prävention eines Mortalitäts- und/oder Morbiditätsereignisses bei einem Patienten, an dem ein schwerer chirurgischer Eingriff vorgenommen wird
EP2399590A1 (de)	2010-06-25	2011-12-28	Aventis Pharma S.A.	Semuloparin zur Prävention eines Mortalitäts- und/oder Morbiditätsereignisses bei einem Patienten, an dem ein schwerer chirurgischer Eingriff vorgenommen wird
EP2399593A1 (de)	2010-06-28	2011-12-28	Aventis Pharma S.A.	Semuloparin zur Prävention eines Mortalitäts- und/oder Morbiditätsereignisses bei einem Patienten, an dem ein schwerer chirurgischer Eingriff vorgenommen wird
CN102399379B (zh) *	2010-09-09	2016-08-31	上海喜恩医药科技发展有限公司	一种肝素衍生的多糖混合物及其制备方法和药物组合物
CA3020369C (en) *	2010-09-14	2019-11-26	Fuso Pharmaceutical Industries, Ltd.	High purity heparin and production method therefor
EP2446891A1 (de)	2010-10-28	2012-05-02	Aventis Pharma S.A.	Semuloparin für Verwendung als eine antithrombotische Behandlung in den großen Bauchoperation mit verbesserter Sicherheit in Bezug auf klinisch relevante Blutungen und starken Blutungen
WO2012055843A1 (en)	2010-10-28	2012-05-03	Aventis Pharma S.A.	Semuloparin for the prevention of major venous thromboembolism in a patient undergoing major abdominal surgery
EP2548561A1 (de)	2011-07-22	2013-01-23	Aventis Pharma S.A.	Semuloparin zur Verbesserung der Überlebenschancen von Patienten mit örtlich fortgeschrittenem Krebs
ES2445494B1 (es) *	2012-08-02	2015-03-06	Rovi Lab Farmaceut Sa	Procedimiento de obtención de heparinas de bajo y muy bajo peso molecular
CN103175925B (zh) *	2013-03-20	2014-12-03	山东辰中生物制药有限公司	依诺肝素钠生产过程中肝素苄基酯的酯化率的检测方法
FR3016632A1 (fr) *	2014-01-21	2015-07-24	IFP Energies Nouvelles	Procede de transformation de polysaccharides en molecules oxygenees en presence de superbases organiques neutres
CZ306662B6 (cs) *	2015-06-26	2017-04-26	Contipro A.S.	Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2478646A2 (fr) *	1980-03-20	1981-09-25	Choay Sa	Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
IL61201A (en) *	1979-10-05	1984-09-30	Choay Sa	Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
FR2482611B1 (fr) *	1980-05-14	1986-03-07	Pharmindustrie	Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4916219A (en) *	1985-03-28	1990-04-10	University Of Iowa Research Foundation	Oligosaccharide heparin fragments as inhibitors of complement cascade
EP0337327A1 (de) *	1988-04-09	1989-10-18	Bioiberica, S.A.	Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
ES2077533B1 (es) *	1994-02-28	1996-07-01	Bioiberica	Procedimiento de obtencion de fracciones de oligosacaridos por despolimerizacion quimica de heparina.
ES2161615B1 (es) *	1999-07-23	2003-03-16	Rovi Lab Farmaceut Sa	Composiciones de heparinas de muy bajo peso molecular.
JP4897991B2 (ja) *	1999-07-23	2012-03-14	ラボラトリオスファルマセウティコスロビソシエダッドアノニマ	超低分子量ヘパリン組成物

2000
- 2000-07-21 FR FR0009572A patent/FR2811992B1/fr not_active Expired - Fee Related
2001
- 2001-07-18 SI SI200130977T patent/SI1307491T1/sl unknown
- 2001-07-18 AP APAP/P/2003/002744A patent/AP1703A/en active
- 2001-07-18 AU AU2001277602A patent/AU2001277602B2/en not_active Ceased
- 2001-07-18 IL IL15392201A patent/IL153922A0/xx unknown
- 2001-07-18 EA EA200300178A patent/EA005995B1/ru not_active IP Right Cessation
- 2001-07-18 DE DE60142340T patent/DE60142340D1/de not_active Expired - Lifetime
- 2001-07-18 HU HU0300755A patent/HUP0300755A3/hu unknown
- 2001-07-18 JP JP2002514199A patent/JP5279160B2/ja not_active Expired - Fee Related
- 2001-07-18 AU AU7760201A patent/AU7760201A/xx active Pending
- 2001-07-18 BR BRPI0112612-1A patent/BR0112612B1/pt not_active IP Right Cessation
- 2001-07-18 PL PL365561A patent/PL202471B1/pl not_active IP Right Cessation
- 2001-07-18 OA OA1200300012A patent/OA12340A/fr unknown
- 2001-07-18 EP EP01955436.9A patent/EP1307491B2/de not_active Expired - Lifetime
- 2001-07-18 WO PCT/FR2001/002332 patent/WO2002008295A1/fr not_active Ceased
- 2001-07-18 UA UA2003010495A patent/UA74836C2/uk unknown
- 2001-07-18 DK DK01955436.9T patent/DK1307491T3/da active
- 2001-07-18 CN CNB018141870A patent/CN1230449C/zh not_active Expired - Fee Related
- 2001-07-18 NZ NZ52402801A patent/NZ524028A/xx not_active IP Right Cessation
- 2001-07-18 DZ DZ013411A patent/DZ3411A1/fr active
- 2001-07-18 MX MXPA03000579A patent/MXPA03000579A/es active IP Right Grant
- 2001-07-18 KR KR1020037000689A patent/KR100853585B1/ko not_active Expired - Fee Related
- 2001-07-18 PT PT01955436T patent/PT1307491E/pt unknown
- 2001-07-18 ES ES01955436.9T patent/ES2347134T5/es not_active Expired - Lifetime
- 2001-07-18 AT AT01955436T patent/ATE470679T1/de active
- 2001-07-18 YU YU2903A patent/YU2903A/sh unknown
- 2001-07-18 HR HR20030019A patent/HRP20030019A2/xx not_active Application Discontinuation
- 2001-07-18 CA CA2416673A patent/CA2416673C/fr not_active Expired - Fee Related
- 2001-07-19 TW TW090117709A patent/TWI307278B/zh not_active IP Right Cessation
- 2001-07-20 AR ARP010103476A patent/AR029865A1/es active IP Right Grant
2003
- 2003-01-10 MA MA26996A patent/MA26928A1/fr unknown
- 2003-01-13 IL IL153922A patent/IL153922A/en not_active IP Right Cessation
- 2003-01-20 NO NO20030296A patent/NO20030296L/no not_active Application Discontinuation
- 2003-01-20 EC EC2003004442A patent/ECSP034442A/es unknown
- 2003-01-31 ZA ZA200300898A patent/ZA200300898B/en unknown
2004
- 2004-05-19 CL CL200401154A patent/CL2004001154A1/es unknown
2010
- 2010-09-09 CY CY20101100819T patent/CY1110774T1/el unknown

Also Published As

Publication number	Publication date
AU2001277602B2 (en)	2007-07-19
EA200300178A1 (ru)	2003-06-26
EP1307491A1 (de)	2003-05-07
ES2347134T5 (es)	2014-06-24
HUP0300755A2 (hu)	2003-12-29
HRP20030019A2 (en)	2005-10-31
AP2003002744A0 (en)	2003-03-31
FR2811992B1 (fr)	2003-07-04
ZA200300898B (en)	2004-04-30
IL153922A (en)	2010-05-17
NO20030296D0 (no)	2003-01-20
HK1059273A1 (en)	2004-06-25
CN1447820A (zh)	2003-10-08
KR100853585B1 (ko)	2008-08-21
CA2416673C (fr)	2011-06-14
BR0112612B1 (pt)	2011-07-12
YU2903A (sh)	2006-03-03
MXPA03000579A (es)	2003-06-06
CY1110774T1 (el)	2015-06-10
HUP0300755A3 (en)	2004-03-01
IL153922A0 (en)	2003-07-31
DE60142340D1 (de)	2010-07-22
CN1230449C (zh)	2005-12-07
DZ3411A1 (fr)	2002-01-31
AP1703A (en)	2007-02-26
PL365561A1 (en)	2005-01-10
PL202471B1 (pl)	2009-06-30
WO2002008295A1 (fr)	2002-01-31
EP1307491B2 (de)	2014-05-07
MA26928A1 (fr)	2004-12-20
EA005995B1 (ru)	2005-08-25
JP2004504451A (ja)	2004-02-12
DK1307491T3 (da)	2010-10-11
BR0112612A (pt)	2003-07-29
EP1307491B1 (de)	2010-06-09
CL2004001154A1 (es)	2005-05-27
ECSP034442A (es)	2003-03-10
UA74836C2 (en)	2006-02-15
NZ524028A (en)	2004-12-24
AR029865A1 (es)	2003-07-16
ES2347134T3 (es)	2010-10-26
KR20030040364A (ko)	2003-05-22
FR2811992A1 (fr)	2002-01-25
ATE470679T1 (de)	2010-06-15
SI1307491T1 (sl)	2010-10-29
PT1307491E (pt)	2010-09-10
NO20030296L (no)	2003-01-20
JP5279160B2 (ja)	2013-09-04
AU7760201A (en)	2002-02-05
TWI307278B (en)	2009-03-11
CA2416673A1 (fr)	2002-01-31

Publication	Publication Date	Title
CA2416673C (fr)	2011-06-14	Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
CA2501546C (fr)	2012-04-03	Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
EP0287477B1 (de)	1994-11-02	Heparine mit niedrigem Molekulargewicht und regelmässiger Struktur, ihre Herstellung und biologische Verwendungen
EP0116801B1 (de)	1987-04-01	Depolymerisiertes und supersulfatiertes Heparin, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen
EP0044228B1 (de)	1985-02-13	Zur Herstellung von Arzneimitteln verwendbare Heparin-Ester und Verfahren zu deren Herstellung
US20110152509A1 (en)	2011-06-23	Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FR2684385A1 (fr)	1993-06-04	Heparosanes-n,o-sulfates de haute masse moleculaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP1651677B1 (de)	2010-11-10	Mischungen aus von heparin abgeleiteten oligosacchariden, herstellung davon und pharmazeutische zusammensetzungen, die die mischungen enthalten
EP0116251B1 (de)	1987-12-16	Verfahren zum Depolymerisieren und Sulfatieren von Polysacchariden
EP0138632A2 (de)	1985-04-24	Komplexe, welche Oligosaccharide enthalten, ihre Herstellung und ihre biologische und biochemische Verwendung
FR2935387A1 (fr)	2010-03-05	Hexadecasaccharides a activite antithrombotique comprenant une liaison covalente avec une chaine amine
NZ537411A (en)	2006-10-27	Heparin-derived polysaccharide mixtures and preparation method
FR2572080A1 (fr)	1986-04-25	Procede de preparation de compositions de mucopolysaccharides dotees d'une activite antithrombotique elevee, les compositions obtenues et leur application en tant que medicaments
EP2614089A1 (de)	2013-07-17	Biotinylierte polysaccharide mit antithrombotischer wirkung und erhöhter stoffwechselstabilität